Bridgeway Capital Management, LLC Protalix Bio Therapeutics, Inc. Transaction History

Bridgeway Capital Management, LLC

$4.76 Billion
Q1 2024

A detailed history of Bridgeway Capital Management, LLC transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 183,790 shares of PLX stock, worth $192,979. This represents 0.0% of its overall portfolio holdings.

Number of Shares

183,790

Previous 208,790 11.97%

Holding current value

$192,979

Previous $371,000 37.74%

% of portfolio

0.0%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.22 - $1.82 $30,500 - $45,500	-25,000 Reduced 11.97%	183,790 $231,000
Q4 2023 Feb 14, 2024	BUY	$1.34 - $1.85 $67,000 - $92,500	50,000 Added 31.49%	208,790 $371,000
Q2 2023 Aug 14, 2023	BUY	$2.0 - $3.36 $50,000 - $84,000	25,000 Added 18.69%	158,790 $317,000
Q3 2022 Nov 14, 2022	SELL	$1.03 - $1.24 $25,750 - $31,000	-25,000 Reduced 15.74%	133,790 $139,000
Q2 2022 Aug 15, 2022	BUY	$1.02 - $1.56 $132,600 - $202,800	130,000 Added 451.55%	158,790 $173,000

Q1 2022 May 16, 2022	BUY	$0.81 - $1.17 $23,319 - $33,684	28,790 New	28,790 $31,000
Q4 2021 Feb 14, 2022	SELL	$0.81 - $1.33 $47,700 - $78,323	-58,890 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$1.31 - $1.87 $438,850 - $626,450	-335,000 Reduced 85.05%	58,890 $78,000
Q2 2021 Aug 16, 2021	BUY	$1.86 - $6.22 $169,816 - $567,879	91,299 Added 30.17%	393,890 $752,000
Q1 2021 May 17, 2021	BUY	$3.58 - $6.45 $322,200 - $580,500	90,000 Added 42.33%	302,591 $1.35 Million
Q3 2020 Nov 16, 2020	BUY	$3.37 - $3.93 $129,071 - $150,519	38,300 Added 21.97%	212,591 $823,000
Q2 2020 Aug 14, 2020	BUY	$2.19 - $4.5 $185,709 - $381,595	84,799 Added 94.76%	174,291 $661,000
Q1 2020 May 15, 2020	BUY	$2.1 - $4.61 $187,933 - $412,558	89,492 New	89,492 $210,000

Others Institutions Holding PLX

# of Institutions

Shares Held

9.27M

Call Options Held

40.6K

Put Options Held

10.1K

View Full List

About Protalix BioTherapeutics, Inc.

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $52.2M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

More about PLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.

Account

Bridgeway Capital Management, LLC Protalix Bio Therapeutics, Inc. Transaction History